You are here: Home » Current Affairs » Coronavirus » News
Business Standard

All risks paid off, India proud: SII, Bharat Biotech on Covid vaccine nod

With the government approving two Covid-19 vaccines for emergency use, Serum Institute said it is ready to roll out Covishield vaccine in India in the coming weeks

Topics
Serum Institute of India | Bharat Biotech | Coronavirus Vaccine

Press Trust of India  |  New Delhi 

Coronavirus vaccine
Covid-19 vaccine

With the government approving two COVID-19 vaccines for emergency use, Serum Institute on Sunday said it is ready to roll out Covishield vaccine in India in the coming weeks, while termed the nod to Covaxin as a giant leap for novel product development.

Even as the two companies gear up to roll out the vaccines, another homegrown pharma major Zydus Cadila said it has received Drug Controller General of India (DCGI) approval to initiate Phase III clinical trials of its COVID-19 vaccine ZyCoV-D.

Pune-based vaccine major (SII) had entered into a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine Covishield.

"Happy new year, everyone! All the risks @SerumInstIndia took with stockpiling the vaccine, have finally paid off. COVISHIELD, India's first COVID-19 vaccine is approved, safe, effective and ready to roll-out in the coming weeks," SII CEO Adar Poonawalla said in a tweet.

The company has already stockpiled around 50 million dosages of the vaccine and aims to produce up to 100 million dosages per month by March next year.

The Oxford-AstraZeneca vaccine has already been approved by the UK government.

Commending SII for its approach on the vaccine, Mahindra group Chairman Anand Mahindra tweeted, "Risk-taking is a fundamental characteristic of business. A bet can go either way but when it succeeds it's hugely rewarding. @adarpoonawalla took a huge risk in creating capacity. But his bet was not just about financial rewards. It will help save millions of lives. A salute".

Reacting to the move by the DCGI, Chairman and Managing Director Krishna Ella said, "The approval of COVAXIN for emergency use is a giant leap for innovation and novel product development in India. It is a proud moment for the nation and a great milestone in India's scientific capability, a kickstart to the innovation ecosystem in India".

While this vaccine addresses an unmet medical need during this pandemic, the company's goal is to provide global access to populations that need it the most, Ella said in a statement.

Covaxin has generated excellent safety data with robust immune responses to multiple viral proteins that persist, Ella added.

Covaxin has been indigenously developed by in collaboration with the Indian Council of Medical Research (ICMR).

The phase-III human clinical trials of Covaxin began in mid-November.

Bharat Biotech aims to recruit 26,000 volunteers across the country for the phase-III trials.

It has already crossed the 23,000-volunteers mark so far.

The Hyderabad-based firm said Covaxin has been evaluated in around 1,000 subjects in phase-I and phase-II clinical trials, with promising safety and immunogenicity results, with acceptance in international peer-reviewed scientific journals.

The approval of the two vaccines the DCGI was given on the basis of recommendations submitted by a COVID-19 subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).

"After adequate examination, CDSCO has decided to accept the recommendations of the Expert Committee and accordingly, vaccines of M/s Serum and M/s Bharat Biotech are being approved for restricted use in emergency situation," DCGI Dr V G Somani said in a press conference.

This paves the way for the roll-out of at least two vaccines in India in the coming days.

Meanwhile, Zydus Cadila said it has received DCGI approval to initiate phase III clinical trials of its COVID-19 vaccine ZyCoV-D. It will be initiating a phase III clinical trial in around 30,000 volunteers.

ZyCoV-D was found to be safe, well-tolerated and immunogenic in phase I and II clinical trials, Zydus Cadila said in a statement.

The phase II study of ZyCoV-D had been conducted in over 1,000 healthy adult volunteers as part of the adaptive Phase I/II dose-escalation, multi-centric, randomised, double-blind placebo-controlled study, the drug firm said.

The trial has reviewed by an independent data safety monitoring board (DSMB) and reports were submitted to the Central Drugs Standard Control Organisation (CDSCO) regularly for the update on safety outcome.

"We are reaching a critical milestone in our vaccine development programme and towards our goal of helping people fight the pandemic with an indigenously discovered, safe and efficacious vaccine," Zydus Group Chairman Pankaj R Patel said.

The launch of the Phase 3 trial will determine the efficacy of the company's vaccine in preventing COVID-19, which continues to pose a major threat world over, he added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sun, January 03 2021. 18:20 IST
RECOMMENDED FOR YOU